JP3219181B2 - Stabilization method of cholesterol oxidase - Google Patents
Stabilization method of cholesterol oxidaseInfo
- Publication number
- JP3219181B2 JP3219181B2 JP00183595A JP183595A JP3219181B2 JP 3219181 B2 JP3219181 B2 JP 3219181B2 JP 00183595 A JP00183595 A JP 00183595A JP 183595 A JP183595 A JP 183595A JP 3219181 B2 JP3219181 B2 JP 3219181B2
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol oxidase
- lysine
- cholesterol
- serum albumin
- bovine serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010089254 Cholesterol oxidase Proteins 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 22
- 230000006641 stabilisation Effects 0.000 title description 4
- 238000011105 stabilization Methods 0.000 title description 4
- 239000004472 Lysine Substances 0.000 claims description 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 22
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 16
- 229940098773 bovine serum albumin Drugs 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000000087 stabilizing effect Effects 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 102000003992 Peroxidases Human genes 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 150000002989 phenols Chemical class 0.000 claims description 4
- 108010055297 Sterol Esterase Proteins 0.000 claims description 3
- 102000000019 Sterol Esterase Human genes 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 229960003646 lysine Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 239000008176 lyophilized powder Substances 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000007990 PIPES buffer Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- STBWJPWQQLXSCK-UHFFFAOYSA-N 3-(n-ethyl-3-methoxyanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(OC)=C1 STBWJPWQQLXSCK-UHFFFAOYSA-N 0.000 description 1
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 1
- IBSUMVZKDLDAEK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(C)=C1 IBSUMVZKDLDAEK-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- UTCHTUKMXVXEBB-UHFFFAOYSA-N OC(CCC1=C(N)C=CC=C1OC)S(=O)(=O)O Chemical compound OC(CCC1=C(N)C=CC=C1OC)S(=O)(=O)O UTCHTUKMXVXEBB-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- KGFAREHEJGDILZ-UHFFFAOYSA-N n,n-diethyl-3-methoxyaniline Chemical compound CCN(CC)C1=CC=CC(OC)=C1 KGFAREHEJGDILZ-UHFFFAOYSA-N 0.000 description 1
- CIPVVROJHKLHJI-UHFFFAOYSA-N n,n-diethyl-3-methylaniline Chemical compound CCN(CC)C1=CC=CC(C)=C1 CIPVVROJHKLHJI-UHFFFAOYSA-N 0.000 description 1
- ZPEDSBOBSNNATM-UHFFFAOYSA-N n-[2-(n-ethyl-3-methylanilino)ethyl]acetamide Chemical compound CC(=O)NCCN(CC)C1=CC=CC(C)=C1 ZPEDSBOBSNNATM-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、コレステロールオキシ
ダーゼの安定化法に関し、特に臨床的に、内分泌疾患や
代謝異常の診断の指標となっている体液中のコレステロ
ールの測定等に用いられるコレステロールオキシダーゼ
の安定化法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for stabilizing cholesterol oxidase. It relates to the stabilization method.
【0002】[0002]
【従来の技術】コレステロールオキシダーゼは、臨床的
に、内分泌疾患や代謝異常の診断の指標となっている体
液中のコレステロールの測定等に用いられる酵素であ
る。従来からコレステロールオキシダーゼの安定化法と
しては、アルカリ金属塩、アルカリ土類金属塩の添加
(特公昭57-13272号公報)、牛血清アルブミン、デキス
トラン、ポリエチレングリコールの添加(特開平6-6284
6 号公報)が知られている。しかし、これらの物質の添
加では、安定化が充分ではなく、保存期間中に酵素剤の
活性の低下ならびに濁りの生成などの問題点があった。
特に濁りにおいては記載がなく根本的な解決がなされて
いなかった。2. Description of the Related Art Cholesterol oxidase is an enzyme used clinically for measuring cholesterol in body fluids, which is used as an index for diagnosis of endocrine diseases and metabolic disorders. Conventional methods for stabilizing cholesterol oxidase include the addition of alkali metal salts and alkaline earth metal salts (Japanese Patent Publication No. 57-13272), the addition of bovine serum albumin, dextran, and polyethylene glycol (JP-A-6-6284).
No. 6) is known. However, the addition of these substances is not sufficient for stabilization, and there are problems such as a decrease in the activity of the enzyme agent during storage and generation of turbidity.
In particular, there was no description for turbidity, and no fundamental solution had been made.
【0003】[0003]
【発明が解決しようとする課題】本発明はコレステロー
ルオキシダーゼの安定化法に関し、その目的とするとこ
ろは長期間の保存によっても酵素活性が低下しない、か
つ、濁りが生じない安定な酵素剤を提供することにあ
る。ここで言う安定化とは酵素活性の保持と変性などに
よる酵素剤からの濁り生成の抑制の2点を指す。SUMMARY OF THE INVENTION The present invention relates to a method for stabilizing cholesterol oxidase, and an object of the present invention is to provide a stable enzyme agent which does not decrease its enzymatic activity even after long-term storage and does not produce turbidity. Is to do. The term “stabilization” as used herein refers to two points, namely, retention of enzyme activity and suppression of turbidity generation from the enzyme agent due to denaturation.
【0004】[0004]
【課題を解決するための手段】本発明はコレステロール
オキシダーゼを含む溶液に、(1) 牛血清アルブミンおよ
び(2) 糖類およびアミノ酸からなる群から選択された少
なくとも1種の化合物を添加することを特徴とするコレ
ステロールオキシダーゼの安定化法である。According to the present invention, a solution containing cholesterol oxidase is added with at least one compound selected from the group consisting of (1) bovine serum albumin and (2) saccharides and amino acids. Is a method for stabilizing cholesterol oxidase.
【0005】また本発明はコレステロールオキシダー
ゼ、(1) 牛血清アルブミンおよび(2)糖類およびアミノ
酸からなる群から選択された少なくとも1種の化合物を
含有することを特徴とするコレステロールオキシダーゼ
製剤である。[0005] The present invention is also a cholesterol oxidase preparation characterized by containing at least one compound selected from the group consisting of cholesterol oxidase, (1) bovine serum albumin and (2) saccharides and amino acids.
【0006】さらに本発明はコレステロールエステラー
ゼ製剤、(1) 牛血清アルブミンおよび(2) 糖類およびア
ミノ酸からなる群から選択された少なくとも1種の化合
物を含有するコレステロールオキシダーゼ製剤、ペルオ
キシダーゼ、4−アミノアンチピリンおよびアニリン誘
導体またはフェノール誘導体および緩衝液からなるコレ
ステロール測定用試薬キットである。The present invention further provides a cholesterol esterase preparation, a cholesterol oxidase preparation containing (1) bovine serum albumin and (2) at least one compound selected from the group consisting of saccharides and amino acids, peroxidase, 4-aminoantipyrine and This is a reagent kit for measuring cholesterol comprising an aniline derivative or a phenol derivative and a buffer.
【0007】また本発明はコレステロールオキシダーゼ
を含む溶液に、リジンを添加することを特徴とするコレ
ステロールオキシダーゼの安定化法である。Further, the present invention is a method for stabilizing cholesterol oxidase, which comprises adding lysine to a solution containing cholesterol oxidase.
【0008】また本発明は、コレステロールオキシダー
ゼおよびリジンを含有することを特徴とするコレステロ
ールオキシダーゼ製剤である。[0008] The present invention is also a cholesterol oxidase preparation containing cholesterol oxidase and lysine.
【0009】さらに本発明はコレステロールエステラー
ゼ製剤、コレステロールオキシダーゼおよびリジンを含
有するコレステロールオキシダーゼ製剤、ペルオキシダ
ーゼ、4−アミノアンチピリンおよびアニリン誘導体ま
たはフェノール誘導体および緩衝液からなるコレステロ
ール測定用試薬キットである。Further, the present invention is a reagent kit for measuring cholesterol comprising a cholesterol esterase preparation, a cholesterol oxidase preparation containing cholesterol oxidase and lysine, peroxidase, 4-aminoantipyrine and an aniline derivative or a phenol derivative and a buffer.
【0010】本発明に使用するコレステロールオキシダ
ーゼとしては、如何なる起源のものでもよいが、例えば
ストレプトマイセス属、コリネバクテリウム属、ブレビ
バクテリウム属、ノカルディア属等の微生物により生産
されるコレステロールオキシダーゼがある。これらの微
生物を培養して得られるコレステロールオキシダーゼ含
有培養物、該培養物を常法により抽出して得た粗酵素、
あるいは該粗酵素を常法により精製して得られる精製酵
素等が好適に用いられる。さらにこれらの酵素を遺伝子
工学的あるいは化学的、物理的に修飾して得られる酵素
も含まれる。The cholesterol oxidase used in the present invention may be of any origin. For example, cholesterol oxidase produced by microorganisms such as Streptomyces, Corynebacterium, Brevibacterium and Nocardia is used. is there. A cholesterol oxidase-containing culture obtained by culturing these microorganisms, a crude enzyme obtained by extracting the culture by a conventional method,
Alternatively, a purified enzyme obtained by purifying the crude enzyme by an ordinary method is suitably used. Furthermore, enzymes obtained by genetically modifying these enzymes or chemically and physically are also included.
【0011】本発明の安定化剤の配合法は、特に制限は
ない。例えばコレステロールオキシダーゼを含む緩衝液
に安定化剤を配合する方法、安定化剤を含む緩衝液にコ
レステロールオキシダーゼを配合する方法、あるいはコ
レステロールオキシダーゼと安定化剤を緩衝液に同時に
添加する方法等がある。本発明では安定化剤を配合した
酵素溶液を凍結乾燥することが好ましい。凍結乾燥の条
件は特に制限はない。The method of compounding the stabilizer of the present invention is not particularly limited. For example, there are a method of adding a stabilizer to a buffer containing cholesterol oxidase, a method of adding cholesterol oxidase to a buffer containing a stabilizer, and a method of adding cholesterol oxidase and a stabilizer simultaneously to the buffer. In the present invention, it is preferable to freeze-dry the enzyme solution containing the stabilizer. The lyophilization conditions are not particularly limited.
【0012】本発明に用いる緩衝液としては、リン酸緩
衝液、グッドバッファー、その他生化学で用いられる緩
衝液なら何れでもよいが、pHは4〜10、望ましくは
pH6.0〜8.0である。The buffer used in the present invention may be any of a phosphate buffer, a good buffer and other buffers used in biochemistry, but the pH is 4 to 10, preferably 6.0 to 8.0. is there.
【0013】本発明に使用する牛血清アルブミン濃度
は、コレステロールオキシダーゼ溶液に対して0.1%
〜20%である。しかし、牛血清アルブミン単独では、
下記表1に示すように37℃一週間保存で88%の残存
活性しかなく、十分な安定化効果が得られなかった。ま
た、濁りの形成においても著しいものであった。The concentration of bovine serum albumin used in the present invention is 0.1% based on the cholesterol oxidase solution.
~ 20%. However, bovine serum albumin alone,
As shown in Table 1 below, after storage at 37 ° C. for one week, only 88% residual activity was observed, and a sufficient stabilizing effect was not obtained. Also, the formation of turbidity was remarkable.
【0014】本発明に使用する糖類としては、グルコー
ス、ガラクトース、キシロース、フラクトース等の単糖
類、ラクトース、マルトース等の二糖類、トレハロー
ス、シュークロース、グルコン酸等の多糖類があるが、
特にシュークロース、グルコース、トレハロース、ラク
トース、グルコン酸ナトリウム、マンニトールが好まし
い。また、その濃度としては、コレステロールオキシダ
ーゼ溶液に対して0.1〜20%である。糖類単独で
は、下記表1に示すように37℃一週間保存で、十分な
安定化効果が得られず、また濁りの形成においても著し
いものであった。糖類は1種または2種以上を組み合わ
せて使用してもよい。The saccharides used in the present invention include monosaccharides such as glucose, galactose, xylose and fructose, disaccharides such as lactose and maltose, and polysaccharides such as trehalose, sucrose and gluconic acid.
Sucrose, glucose, trehalose, lactose, sodium gluconate and mannitol are particularly preferred. The concentration is 0.1 to 20% based on the cholesterol oxidase solution. As shown in Table 1 below, the saccharide alone could not obtain a sufficient stabilizing effect when stored at 37 ° C. for one week, and was remarkable in the formation of turbidity. The saccharides may be used alone or in combination of two or more.
【0015】本発明に使用するアミノ酸もしくはその塩
としてはグリシン、グルタミン酸、リジン等の親水性の
アミノ酸もしくはそのナトリウム、カリウム、アンモニ
ウム等の塩、酢酸塩または塩酸塩等があるが、特にグリ
シンアミノ酢酸塩、リジン塩酸塩が好ましい。その濃度
としては、コレステロールオキシダーゼ溶液に対して
0.1〜20%である。リジン以外のアミノ酸単独で
は、下記表1に示すように37℃一週間保存で、十分な
安定化効果が得られず、また濁りの形成においても著し
いものであった。リジンは単独にても安定化効果および
濁り形成において優れている。アミノ酸は1種または2
種以上を組み合わせて使用してもよい。The amino acids or salts thereof used in the present invention include hydrophilic amino acids such as glycine, glutamic acid and lysine, and salts, acetates and hydrochlorides thereof such as sodium, potassium and ammonium. Salts and lysine hydrochloride are preferred. The concentration is 0.1 to 20% based on the cholesterol oxidase solution. As shown in Table 1 below, when amino acids other than lysine alone were stored at 37 ° C. for one week, a sufficient stabilizing effect was not obtained, and formation of turbidity was remarkable. Lysine alone is excellent in stabilizing effect and turbidity formation. One or two amino acids
A combination of more than one species may be used.
【0016】本発明の好ましい実施態様は、コレステロ
ールオキシダーゼを含む溶液に、(1) 牛血清アルブミン
および(2) 糖類およびアミノ酸からなる群から選択され
た少なくとも1種の化合物を添加し、さらに凍結乾燥す
るコレステロールオキシダーゼの安定化法である。In a preferred embodiment of the present invention, a solution containing cholesterol oxidase is added with at least one compound selected from the group consisting of (1) bovine serum albumin and (2) sugars and amino acids, and further lyophilized. This is a method for stabilizing cholesterol oxidase.
【0017】本発明の別な好ましい実施態様は、コレス
テロールオキシダーゼを含む溶液に、リジンを添加し、
さらに凍結乾燥するコレステロールオキシダーゼの安定
化法である。In another preferred embodiment of the present invention, lysine is added to a solution containing cholesterol oxidase,
Further, it is a method for stabilizing cholesterol oxidase which is freeze-dried.
【0018】また、本発明の別な好ましい実施態様は、
コレステロールオキシダーゼ、(1)牛血清アルブミンお
よび(2) 糖類およびアミノ酸からなる群から選択された
少なくとも1種の化合物を含有するコレステロールオキ
シダーゼ固形製剤である。In another preferred embodiment of the present invention,
A cholesterol oxidase solid preparation containing at least one compound selected from the group consisting of cholesterol oxidase, (1) bovine serum albumin, and (2) sugars and amino acids.
【0019】さらに本発明の別な好ましい実施態様は、
コレステロールオキシダーゼ、リジンを含有するコレス
テロールオキシダーゼ固形製剤である。Still another preferred embodiment of the present invention is:
It is a cholesterol oxidase solid preparation containing cholesterol oxidase and lysine.
【0020】本発明のコレステロール測定用試薬キット
は、コレステロールオキシダーゼの作用により生成した
過酸化水素を公知の種々の方法で測定するものである
が、最も一般的に利用されている方法は、ペルオキシダ
ーゼの存在下、色原体を酸化し、4−アミノアンチピリ
ンなどのカップラーと縮合させて色素を形成させ、比色
定量する方法が挙げられる。この方法に用いられる色原
体としては、フェノール、2−クロロフェノール、4−
クロロフェノール、2,4−ジクロロフェノールなどの
フェノール誘導体、もしくはアニリン、N,N−ジメチ
ルアニリン、N,N−ジエチルアニリン、N,N−ジエ
チル−m−トルイジン、N,N−ジエチル−m−アニシ
ジン、N−エチル−N−(3−メチルフェニル)−N’
−アセチルエチレンジアミン、N−エチル−N−(2−
ヒドロキシ−3−スルホプロピル)−m−アニシジン、
N−エチル−N−(2−ヒドロキシ−3−スルホプロピ
ル)−m−トルイジン、N−エチル−N−スルホプロピ
ル−m−トルイジン、N−エチル−N−スルホプロピル
−m−アニシジンなどのアニリン誘導体が挙げられる。
過酸化水素の測定試薬は上記試薬に限られない。The reagent kit for measuring cholesterol of the present invention measures hydrogen peroxide generated by the action of cholesterol oxidase by various known methods. The most commonly used method is the method of measuring peroxidase. In the presence, a method of oxidizing a chromogen, condensing it with a coupler such as 4-aminoantipyrine to form a dye, and performing colorimetric determination. Chromogens used in this method include phenol, 2-chlorophenol, and 4-chlorophenol.
Phenol derivatives such as chlorophenol and 2,4-dichlorophenol, or aniline, N, N-dimethylaniline, N, N-diethylaniline, N, N-diethyl-m-toluidine, N, N-diethyl-m-anisidine , N-ethyl-N- (3-methylphenyl) -N '
-Acetylethylenediamine, N-ethyl-N- (2-
(Hydroxy-3-sulfopropyl) -m-anisidine;
Aniline derivatives such as N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-toluidine, N-ethyl-N-sulfopropyl-m-toluidine, N-ethyl-N-sulfopropyl-m-anisidine Is mentioned.
The reagent for measuring hydrogen peroxide is not limited to the above reagent.
【0021】[0021]
【実施例】以下、本発明を実施例により詳細に説明す
る。実施例1 コレステロールオキシダーゼ溶液(2,000U/ml) 1ml に、
牛血清アルブミン(以下BSA と略す。オルガノテクニカ
製)を17.2mgとシュークロース、グルコース、トレハロ
ース、ラクトース、グルコン酸Na、マンニトール、グル
タミン酸Na、グリシンからなる群から選ばれた一種を、
それぞれ14.7mg添加混合し、凍結乾燥を行い、凍結乾燥
粉末を50mg得た。また同様にして、それぞれの添加剤の
み単独を添加し、または添加せずに、凍結乾燥粉末を得
た。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below in detail with reference to embodiments. Example 1 Cholesterol oxidase solution (2,000 U / ml)
17.2 mg of bovine serum albumin (hereinafter abbreviated as BSA; manufactured by Organotechnica) and one kind selected from the group consisting of sucrose, glucose, trehalose, lactose, sodium gluconate, mannitol, sodium glutamate, and glycine,
Each 14.7 mg was added, mixed and freeze-dried to obtain 50 mg of a freeze-dried powder. Similarly, a lyophilized powder was obtained with or without the addition of each additive alone.
【0022】上記製法で得た牛血清アルブミンと糖類ま
たはアミノ酸を添加したコレステロールオキシダーゼ凍
結乾燥粉末、コレステロールオキシダーゼ溶液にBSA 1
7.2mgのみを添加し凍結乾燥した粉末、糖類またはアミ
ノ酸のみを14.7mg添加し、凍結乾燥した粉末ならびに添
加剤なしのコレステロールオキシダーゼ凍結乾燥粉末を
以下のように比較した。凍結乾燥粉末を37℃にて一週間
保存し、その後の残存活性を測定した。また、該粉末を
保存後、過剰テストとして、該粉末を100U/ml になるよ
うに、50mM PIPESバッファー(pH7.0) に溶解し、その溶
液を37℃に保持し、濁りの生成をOD660で測定し、かつ
目視により濁りを確認した。その結果を表1および表2
に示す。The cholesterol oxidase freeze-dried powder to which bovine serum albumin and sugars or amino acids obtained by the above-mentioned method are added, and BSA 1
A freeze-dried powder to which only 7.2 mg was added and 14.7 mg of only a saccharide or an amino acid was added, and a freeze-dried powder and a freeze-dried cholesterol oxidase powder without additives were compared as follows. The freeze-dried powder was stored at 37 ° C. for one week, and the residual activity thereafter was measured. Moreover, after saving the powder, as excessive testing, so that the powder in 100 U / ml, dissolved in 50 mM PIPES buffer (pH 7.0), The solution was maintained 37 ° C., the formation of turbidity OD 660 And turbidity was visually observed. Table 1 and Table 2 show the results.
Shown in
【0023】[0023]
【表1】 [Table 1]
【0024】[0024]
【表2】 [Table 2]
【0025】本発明の安定化されたコレステロールオキ
シダーゼ凍結乾燥粉末は、37℃で保存した場合、一週間
にわたって充分な活性を維持すること、濁りの生成も実
用レベルでほとんど問題に成らないレベルまで改善され
たことを確認した。一方、無添加のコレステロールオキ
シダーゼ凍結乾燥粉末は、37℃、一週間保存で、活性が
60%しか残存しておらず、著しい濁りの生成がみられ
た。また、BSA のみ添加した凍結乾燥粉末は、残存活性
が 88%であったが、著しい濁りの生成がみられた。The freeze-dried stabilized cholesterol oxidase powder of the present invention, when stored at 37 ° C., maintains a sufficient activity for one week and improves the formation of turbidity to a practically acceptable level. I confirmed that it was done. On the other hand, freeze-dried cholesterol oxidase powder without additives has a high activity after storage at 37 ° C for one week.
Only 60% remained, and significant turbidity was observed. The lyophilized powder to which only BSA was added had a residual activity of 88%, but marked turbidity was observed.
【0026】実施例2 コレステロールオキシダーゼ溶液(2,000U/ml) 1ml に、
リジンを14.7mg添加混合し、凍結乾燥を行い、凍結乾燥
粉末を50mg得た。また、同様にしてコレステロールオキ
シダーゼ溶液(2,000U/ml) 1ml に、BSAを17.2mgとリジ
ンを14.7mg添加混合し、凍結乾燥を行い、凍結乾燥粉末
を50mg得た。これらの凍結乾燥粉末を37℃にて一週間保
存し、その後の残存活性を測定した。また、該粉末を保
存後、過剰テストとして、該粉末を100U/ml になるよう
に、50mM PIPESバッファー(pH7.0) に溶解し、その溶液
を37℃に保持し、濁りの生成をOD660 で測定し、かつ目
視により濁りを確認した。その結果を表3に示す。 Example 2 1 ml of a cholesterol oxidase solution (2,000 U / ml)
Lysine was added and mixed with 14.7 mg of lysine, and lyophilized to obtain 50 mg of lyophilized powder. Similarly, 17.2 mg of BSA and 14.7 mg of lysine were added to 1 ml of a cholesterol oxidase solution (2,000 U / ml), and the mixture was lyophilized to obtain 50 mg of a lyophilized powder. These freeze-dried powders were stored at 37 ° C. for one week, and the residual activity thereafter was measured. Moreover, after saving the powder, as excessive testing, so that the powder in 100 U / ml, dissolved in 50 mM PIPES buffer (pH 7.0), The solution was maintained 37 ° C., the formation of turbidity OD 660 And turbidity was visually observed. Table 3 shows the results.
【0027】[0027]
【表3】 [Table 3]
【0028】実施例3 コレステロールオキシダーゼ溶液(2,000U/ml) 1ml に、
BSA (オルガノテクニカ製)21.2mgと、リジン16.8mg
(リジン1)または33.6mg(リジン2)を添加混合し、
凍結乾燥を行い、凍結乾燥粉末を得た。得られたコレス
テロールオキシダーゼ凍結乾燥粉末を37℃にて二週間保
存し、その後の残存活性を測定した。また、粉末を保存
後、100U/ml になるように50mMPIPESバッファー(pH7.0)
に溶解し、その溶液を37℃に保持し、濁りの生成をOD
660 で測定した。その結果を表4に示す。[0028]Example 3 1 ml of cholesterol oxidase solution (2,000 U / ml)
21.2 mg of BSA (manufactured by Organotechnica) and 16.8 mg of lysine
(Lysine 1) or 33.6 mg (lysine 2) is added and mixed,
Lyophilization was performed to obtain a lyophilized powder. The choles obtained
Keep freeze dried terol oxidase powder at 37 ° C for 2 weeks
And the remaining activity thereafter was measured. Also save the powder
After that, 50mMPIPES buffer (pH7.0) to 100U / ml
, And the solution is kept at 37 ° C.
660Was measured. Table 4 shows the results.
【0029】[0029]
【表4】 [Table 4]
【0030】本発明により安定化されたコレステロール
オキシダーゼは、37℃で保存した場合、二週間にわたっ
て充分な活性を維持すること、濁りの生成も実用レベル
でほとんど問題に成らないレベルまで改善されたことを
確認した。The cholesterol oxidase stabilized according to the present invention, when stored at 37 ° C., maintains sufficient activity for two weeks, and the formation of turbidity has been improved to a practically acceptable level. It was confirmed.
【0031】実施例4 コレステロールオキシダーゼ溶液(2,000U/ml) 1ml に、
BSA18.6mgおよびリジン14.8mgまたはシュークロース14.
8mgを添加混合し、さらに BSA 18.6mg およびリジンお
よびシュークロースをそれぞれ14.8mg添加混合し、凍結
乾燥を行い、凍結乾燥粉末を得た。 Example 4 1 ml of cholesterol oxidase solution (2,000 U / ml)
BSA 18.6mg and lysine 14.8mg or sucrose 14.
8 mg was added and mixed, and 18.6 mg of BSA and 14.8 mg of lysine and sucrose were added and mixed, respectively, and lyophilized to obtain a lyophilized powder.
【0032】得られたコレステロールオキシダーゼ凍結
乾燥粉末を37℃にて一週間保存し、その後の残存活性を
測定した。また、該粉末を保存後、100U/ml になるよう
に50mM PIPESバッファー(pH7.0) に溶解し、その溶液を
37℃に保持し、濁りの生成をOD660 で測定した。その結
果を表5に示す。The resulting freeze-dried cholesterol oxidase powder was stored at 37 ° C. for one week, and the residual activity thereafter was measured. After storing the powder, the powder was dissolved in 50 mM PIPES buffer (pH 7.0) to a concentration of 100 U / ml.
It was kept at 37 ° C. and the formation of turbidity was measured at OD 660 . Table 5 shows the results.
【0033】[0033]
【表5】 [Table 5]
【0034】本発明により安定化されたコレステロール
オキシダーゼは、37℃で保存した場合、一週間にわたっ
て充分な活性を維持すること、濁りの生成も実用レベル
でほとんど問題に成らないレベルまで改善されたことを
確認した。The cholesterol oxidase stabilized according to the present invention, when stored at 37 ° C., maintains a sufficient activity for one week, and its turbidity has been improved to a practically acceptable level. It was confirmed.
【0035】比較例1 コレステロールオキシダーゼ溶液(2,000U/ml) 1ml に、
塩化ナトリウムをそれぞれ29mg(0.5M)、17.5mg(0.3M)、
8.8mg(0.15M)添加混合し、凍結乾燥を行い、凍結乾燥粉
末を得た。得られた凍結乾燥粉末を37℃にて二週間保存
し、その後の残存活性を測定した。また、粉末を保存
後、100U/ml になるように50mM PIPESバッファー(pH7.
0) に溶解し、その溶液を37℃に保持し、濁りの生成を
目視判定した。その結果を表6に示す。 Comparative Example 1 1 ml of cholesterol oxidase solution (2,000 U / ml)
29 mg (0.5 M) of sodium chloride, 17.5 mg (0.3 M),
8.8 mg (0.15 M) was added, mixed and freeze-dried to obtain a freeze-dried powder. The obtained lyophilized powder was stored at 37 ° C. for two weeks, and the remaining activity thereafter was measured. After storing the powder, add 50 mM PIPES buffer (pH 7.
0), the solution was kept at 37 ° C., and the formation of turbidity was visually judged. Table 6 shows the results.
【0036】[0036]
【表6】 このように、アルカリ金属では濁りの生成が著しい。[Table 6] As described above, formation of turbidity is remarkable in alkali metals.
【0037】[0037]
【発明の効果】本発明ではリジンを添加することによ
り、安定化効果とともに濁りにおいて優れたコレステロ
ールオキシダーゼ製剤を得ることができる。また、従来
から、牛血清アルブミン、糖類、アミノ酸は各種酵素の
安定化剤として知られているが、本発明ではそれらを組
み合わせることにより、単独で用いる場合よりも熱に対
して、一段と優れた安定化効果が見られる。さらに本発
明では、その組み合わせにより、濁りの生成を抑える効
果が非常に高く、安定な酵素製剤を得ることが出来る。
したがって、生化学試薬等として、前処理なしに使用で
きる利点を有する。According to the present invention, by adding lysine, a cholesterol oxidase preparation excellent in turbidity as well as stabilizing effect can be obtained. Bovine serum albumin, saccharides, and amino acids are conventionally known as stabilizers for various enzymes. However, in the present invention, by combining them, more excellent stability against heat than when used alone is obtained. The effect is seen. Further, in the present invention, a stable enzyme preparation having a very high effect of suppressing the generation of turbidity can be obtained by the combination.
Therefore, it has an advantage that it can be used as a biochemical reagent or the like without pretreatment.
フロントページの続き (72)発明者 愛水 重典 福井県敦賀市東洋町10番24号 東洋紡績 株式会社 敦賀バイオ研究所内 審査官 本間 夏子 (56)参考文献 特開 平6−32846(JP,A) 特開 昭55−34001(JP,A) 特開 昭60−224499(JP,A) (58)調査した分野(Int.Cl.7,DB名) C12Q 1/00 - 3/00 Continued on the front page (72) Inventor Shigenori Aizumi 10-24, Toyo-cho, Tsuruga-shi, Fukui Prefecture Toyobo Co., Ltd. Examiner at Tsuruga Bio-Research Laboratory Natsuko Homma JP-A-55-340001 (JP, A) JP-A-60-224499 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) C12Q 1/00-3/00
Claims (6)
に、(1) 牛血清アルブミンおよび(2)リジンを添加する
ことを特徴とするコレステロールオキシダーゼの安定化
法。1. A method for stabilizing cholesterol oxidase, comprising adding (1) bovine serum albumin and (2) lysine to a solution containing cholesterol oxidase.
に、(1) 牛血清アルブミンおよび(2)リジンを添加し、
さらに凍結乾燥する請求項1記載のコレステロールオキ
シダーゼの安定化法。2. A solution containing cholesterol oxidase, comprising adding (1) bovine serum albumin and (2) lysine,
The method for stabilizing cholesterol oxidase according to claim 1, further comprising freeze-drying.
て、牛血清アルブミンを0.1〜20%およびリジンを
0.1〜20%添加する請求項1記載のコレステロール
オキシダーゼの安定化法。3. The method according to claim 1, wherein 0.1 to 20% of bovine serum albumin and 0.1 to 20% of lysine are added to the cholesterol oxidase solution.
清アルブミンおよび(2)リジンを含有することを特徴と
するコレステロールオキシダーゼ製剤。4. A cholesterol oxidase preparation comprising cholesterol oxidase, (1) bovine serum albumin and (2) lysine.
ロールオキシダーゼ製剤。5. The cholesterol oxidase preparation according to claim 4, which is a solid preparation.
牛血清アルブミンおよび(2)リジンを含有するコレステ
ロールオキシダーゼ製剤、ペルオキシダーゼ、4−アミ
ノアンチピリンおよびアニリン誘導体またはフェノール
誘導体および緩衝液からなるコレステロール測定用試薬
キット。6. A cholesterol esterase preparation, (1)
A cholesterol measurement reagent kit comprising a cholesterol oxidase preparation containing bovine serum albumin and (2) lysine, peroxidase, 4-aminoantipyrine and an aniline derivative or a phenol derivative, and a buffer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP00183595A JP3219181B2 (en) | 1995-01-10 | 1995-01-10 | Stabilization method of cholesterol oxidase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP00183595A JP3219181B2 (en) | 1995-01-10 | 1995-01-10 | Stabilization method of cholesterol oxidase |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08187095A JPH08187095A (en) | 1996-07-23 |
JP3219181B2 true JP3219181B2 (en) | 2001-10-15 |
Family
ID=11512623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP00183595A Expired - Lifetime JP3219181B2 (en) | 1995-01-10 | 1995-01-10 | Stabilization method of cholesterol oxidase |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3219181B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR980010429A (en) * | 1996-07-18 | 1998-04-30 | 다나까 모또아끼 | Cholesterol Determination |
JP3206894B2 (en) * | 1996-07-25 | 2001-09-10 | 理化学研究所 | How to heat activate enzymes |
EP1508616B1 (en) * | 1998-04-24 | 2006-10-25 | Sysmex Corporation | Method for stabilizing an aspartate aminotransferase and the corresponding compositions |
EP2236618A3 (en) * | 2001-01-31 | 2011-06-08 | Asahi Kasei Pharma Corporation | Compositions for assaying glycoprotein |
WO2003004633A1 (en) * | 2001-07-02 | 2003-01-16 | Asahi Kasei Kabushiki Kaisha | Method of stabilizing alkaline phosphatase |
JP4565311B2 (en) * | 2002-10-03 | 2010-10-20 | 東洋紡績株式会社 | Enzyme stabilization method and composition |
MY142014A (en) * | 2004-04-08 | 2010-08-16 | Nisshin Oillio Group Ltd | A lipase powder, methods for producing the same and use thereof |
JP2008206491A (en) * | 2007-02-28 | 2008-09-11 | Toyobo Co Ltd | METHOD FOR STABILIZING p-HYDROXYBENZOATE HYDROXYLASE |
EP2042870A1 (en) | 2007-09-28 | 2009-04-01 | Fujifilm Corporation | Method of high sensitive immunoassay |
JP4865880B2 (en) * | 2010-04-05 | 2012-02-01 | デンカ生研株式会社 | Method for quantifying cholesterol in low density lipoprotein |
DK2772536T3 (en) | 2011-10-28 | 2017-06-12 | Sunstar Engineering Inc | COMPOSITION AND PROCEDURE FOR PREPARING SAME |
US9683228B2 (en) | 2012-04-27 | 2017-06-20 | Kyowa Medex Co., Ltd. | Method for stabilizing cholesterol oxidase |
JP6081515B2 (en) | 2014-04-10 | 2017-02-15 | ミヨシ油脂株式会社 | Method for using biocatalyst solution using ionic liquid and solvent for biocatalyst |
CN104483314A (en) * | 2014-12-25 | 2015-04-01 | 桂林中辉科技发展有限公司 | Method for improvingthermal stability of test strips for detecting peroxide value of cooking oil |
CN106498087B (en) * | 2016-12-30 | 2020-01-07 | 广东环凯生物科技有限公司 | Clostridium perfringens dry powder LAMP rapid detection kit and method of use |
JP6349452B1 (en) | 2017-11-29 | 2018-06-27 | ヤマサ醤油株式会社 | L-glutamate oxidase dry composition |
CN108008125A (en) * | 2017-12-18 | 2018-05-08 | 江苏浩欧博生物医药股份有限公司 | It is a kind of suitable for lyophilized working solution and immunomagnetic beads dried frozen aquatic products of immunomagnetic beads and preparation method thereof |
JP7525254B2 (en) | 2019-11-14 | 2024-07-30 | ミヨシ油脂株式会社 | Organic ammonium salt and biological sample treatment agent using the same |
JP7450898B2 (en) | 2020-10-06 | 2024-03-18 | エンバイロ・ビジョン株式会社 | Wastewater treatment equipment and wastewater treatment method |
CN113528499A (en) * | 2021-05-29 | 2021-10-22 | 北京华宇亿康生物工程技术有限公司 | Buffer system capable of stably storing Hexokinase (HK) |
-
1995
- 1995-01-10 JP JP00183595A patent/JP3219181B2/en not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
US11994343B2 (en) | 2019-03-14 | 2024-05-28 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Also Published As
Publication number | Publication date |
---|---|
JPH08187095A (en) | 1996-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3219181B2 (en) | Stabilization method of cholesterol oxidase | |
IL43054A (en) | Reagent and process for the enzymatic determination of glucose | |
EP1213358A2 (en) | Method and kit for the determination of a biological component | |
JPH0236228B2 (en) | ||
EP0012446A1 (en) | Acidic uricase, its production and its use for the determination of uric acid | |
JP3125610B2 (en) | Method for stabilizing L-methionine γ-lyase | |
Fry et al. | Isolation and characterization of glycolic acid oxidase from human liver | |
US5804402A (en) | Reagent | |
JPS5814198B2 (en) | NADH-peroxidase, its production method and method for measuring H↓2O↓2 using the same | |
JP3696267B2 (en) | Method for stabilizing bioactive protein | |
JPS6123995B2 (en) | ||
Schott et al. | Enzymatic properties of L-kynurenine 3-hydroxylase (EC 1.14. 1.2) in Neurospora crassa | |
JPS5925684A (en) | Stable p-hydroxybenzoic acid hydroxylase composition | |
JP3181801B2 (en) | Pyruvate orthophosphate dikinase and method for producing the same | |
JPS6233880B2 (en) | ||
JP3216735B2 (en) | Novel ascorbate oxidase | |
Chen et al. | Alkylamidase of sheep liver | |
JPH0231954B2 (en) | KOSONOANTEIKAZAIOYOBIKOSOHOZONHOHO | |
JP4284384B2 (en) | Method and composition for stabilizing glycerophosphate oxidase | |
Snoswell | [58] dl-Lactate dehydrogenases (NAD+-independent) from Lactobacillus arabinosus | |
JPS60156386A (en) | Stabilized glycerophosphate oxidase composition | |
JP2000032980A (en) | Stabilization of glucose-6-phosphate dehydrogenase and composition containing the same | |
Teichert et al. | The influence of acclimation temperature on carp liver 3-hydroxy-3-methylglutaryl coenzyme A reductase | |
JPS62111686A (en) | Stable guanase composition | |
JP2002095498A (en) | Method for assaying inulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090810 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090810 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110810 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110810 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120810 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130810 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term |